Ketorolac tromethamine + levofloxacin is under clinical development by NTC and currently in Phase II for Bacterial Conjunctivitis. According to GlobalData, Phase II drugs for Bacterial Conjunctivitis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketorolac tromethamine + levofloxacin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ketorolac tromethamine + levofloxacin overview

Fixed dose combination of ketorolac tromethamine and levofloxacin is under development for the treatment of bacterial conjunctivitis. It is formulated as eye drops and administered through ophthalmic route. Ketorolac tromethamine acts by targeting enzymecylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) and levofloxacin acts by targeting bacterial DNA gyrase and topoisomerase IV.

NTC overview

NTC is a pharmaceutical company. It researches, develops, registers and commercialization of drugs, medical devices and food supplements. The company’s pipeline products include NTC041, NTC014, NTC011, NTC012 and NTC013. Its product indications comprise post-cataract surgery, bacterial conjunctivitis, acute otitis media with STMP and ocular infections. NTC offers products in ophthalmology therapeutic areas comprising eye surgery, eye infections and inflammation, allergy, blepharitis and ocular discomfort. It also offers products in other therapeutic areas such as pediatrics, gynecology and gastroenterology. The company operates in Spain and Italy. NTC is headquartered in Milan, Lombardia, Italy.

For a complete picture of Ketorolac tromethamine + levofloxacin’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.